FUJIFILM Cellular Dynamics Announces the Appointment of Dr. Ilyas Singeç as Chief Scientific Officer

FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSCs), today announces the appointment of Ilyas Singeç, M.D., as chief scientific officer effective September 12. In this newly created strategic role, Dr. Singeç will define the Company’s future iPSC technological pipeline. In his role as part of the Company’s executive leadership team, he will also help drive business strategy with the goal of transforming scientific research and healthcare by using iPSC technologies.

“We are thrilled to welcome Dr. Singeç to the FUJIFILM Cellular Dynamics family,” said Tomoyuki Hasegawa, chief executive officer, FUJIFILM Cellular Dynamics, Inc. “Dr. Singeç brings over 20 years of experience in cell and molecular biology, and extensive stem cell expertise, which will be instrumental as FUJIFILM Cellular Dynamics expands our application of leading-edge iPSC technologies to continue innovating in this field.”

Prior to joining FUJIFILM Cellular Dynamics, Dr. Singeç served as the inaugural director of the Stem Cell Translation Laboratory (SCTL) at the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). In his role at NCATS, he focused on developing innovative strategies to advance the translation of iPSC research into preclinical and clinical applications including drug discovery, gene editing, cell therapy and others. Prior to joining NCATS, he worked in the pharmaceutical industry and academic institutions such as Pfizer and the Sanford Burnham Prebys Medical Discovery Institute. Dr. Singeç earned his M.D. and Ph.D. (summa cum laude) in Germany at the Universities of Bonn and Freiburg, completing his residency in clinical neuropathology and neuroanatomy in Freiburg.

“FUJIFILM Cellular Dynamics is a pioneer in developing iPSC technology for scientific and translational research,” said Dr. Singeç. “I am truly excited to join this world-class team of creative and dedicated scientists. I look forward to working alongside the team to develop next-generation iPSC technologies and propel human biology-based research and therapeutic applications.”